论文部分内容阅读
目的-从病理组织-学和-免疫组织化学改变的角度分析拉米夫定的疗效。方法13例rrrrrrrrrn慢性乙型肝炎患者予拉米夫定100mg/d,连用1年。治疗前后在超声导向下行肝脏活检,切片HE染rrrrrrrrrn色和网纤染色,对炎症活动度(HAI)和纤维化程度作计分评价。HBsAg和HBcAg用免疫组化rrrrrrrrrn(LSAB)法检测。结果13例患者拉米夫定治疗后血清HBVDNA全部转为阴性(<1.6pg/ml),组rrrrrrrrrn织学炎症活动度计分由5.23±2.99降为3.54±1.55(P<0.05);纤维化程度计分由2.61±1.15降rrrrrrrrrn为1.92±1.21(P>0.05)。免疫组化5例HBsAg由弥漫性胞浆型表达转变为散在包涵体样型表达,rrrrrrrrrn其中4例HBcAg由胞浆型表达为主转变为核型表达为主。结论拉米夫定持续用药可使肝组织炎rrrrrrrrrn症活动度计分尤其是碎屑坏死改善(P<0.05);血清HBVDNA阴转,肝组织HBsAg、HBcAg表达量rrrrrrrrrn减少
Objective - To analyze the efficacy of lamivudine from the perspective of histopathology and immunohistochemistry. Methods 13 patients with chronic hepatitis B to lamivudine 100mg / d, once every 1 year. Before and after treatment in the liver ultrasound biopsy biopsy, HE staining and stained sections of fiber staining, degree of inflammation (HAI) and degree of fibrosis Scoring evaluation. HBsAg and HBcAg were detected by immunohistochemistry (LSAB). Results Serum HBVDNA turned negative (<1.6pg / ml) after lamivudine treatment in 13 patients. The histological inflammatory activity The score decreased from 5.23 ± 2.99 to 3.54 ± 1.55 (P <0.05). The score of fibrosis was 2.61 ± 1.15 1.21 (P> 0.05). Immunohistochemical 5 cases of HBsAg from diffuse cytoplasmic expression into scattered inclusion body type expression, of which 4 cases of HBcAg from cytoplasmic Expression as the main change to karyotype expression. Conclusion lamivudine continued treatment can improve the activities of liver disease scoring activity, especially debris necrosis improved (P <0.05); serum HBVDNA negative, liver tissue HBsAg, HBcAg expression r r r r r r r r n decrease